Jay Ambe Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -12.35%
- Profit Growth -21.95%
- Ebitda -9.64%
- Net Worth 125.87%
- Total Assets 3.16%
About Jay Ambe Biotech
Jay Ambe Biotech Private Limited (JABPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 January 2017 (Eight years and one month 1 days old ). Its registered office is in Agra, Uttar Pradesh, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kalpanath Khuntia and Teja Singh serve as directors at the Company.
Company Details
-
Location
Agra, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U01110UP2017PTC088956
-
Company No.
088956
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Jan 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
What products or services does Jay Ambe Biotech Private Limited offer?
Jay Ambe Biotech Private Limited offers a wide range of products and services, including Fresh, Dried & Preserved Fruits, Fresh Fruits, Fresh Flowers, Plants & Trees, Fruit Plants, Fresh, Dried & Preserved Vegetables, Fresh Vegetables, Outdoor Plant, Agricultural & Farm Consultants, Agro Farming Services, Wood, Plywood, Veneer & Laminates.
Who are the key members and board of directors at Jay Ambe Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kalpanath Khuntia
|
Director | 28-Dec-2017 | Current |
|
Teja Singh
|
Director | 06-Jan-2017 | Current |
Financial Performance of Jay Ambe Biotech.
Jay Ambe Biotech Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 12.35% decrease. The company also saw a substantial fall in profitability, with a 21.95% decrease in profit. The company's net worth Soared by an impressive increase of 125.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jay Ambe Biotech?
In 2020, Jay Ambe Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jay Ambe Biotech?
Unlock and access historical data on people associated with Jay Ambe Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jay Ambe Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jay Ambe Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
